^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    BAP1 mutation + FGFR2 fusion

    i
    Other names: FGFR2, BEK, CD332, CEK3, CFD1, ECT1, JWS, K-SAM, KGFR, TK14, TK25, Fibroblast growth factor receptor 2, BAP1, BRCA1 Associated Protein 1, BRCA1 Associated Protein-1 (Ubiquitin Carboxy-Terminal Hydrolase), Ubiquitin Carboxyl-Terminal Hydrolase BAP1, Cerebral Protein 6, Ubiquitin Carboxy-Terminal Hydrolase, BRCA1-Associated Protein 1, Cerebral Protein-13, HUCEP-13, KIAA0272, Hucep-6, UCHL2
    Entrez ID:
    2263; 8314
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    over1year
    Spatial immunophenotypes predict clinical outcome in intrahepatic cholangiocarcinoma. (PubMed, JHEP Rep)
    By integrating genomic and transcriptomic data, phenotype-specific biological behaviours and potential immune escape mechanisms were analysed. Our findings provide a rationale to develop personalized therapies for iCCA.
    Clinical data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • FGFR2 (Fibroblast growth factor receptor 2) • BAP1 (BRCA1 Associated Protein 1) • TGFB1 (Transforming Growth Factor Beta 1)
    |
    PD-L1 expression • FGFR2 mutation • FGFR2 fusion • BAP1 mutation • BAP1 mutation + FGFR2 fusion
    almost3years
    Genomic Profiling of Pancreatic Ductal Adenocarcinoma, Intrahepatic and Extrahepatic Cholangiocarcinoma (USCAP 2022)
    "Our data show that the presence of IDH1, BAP1 mutation and FGFR2 fusion supports the diagnosis of iCCA. Tumors with loss of CDKN2A/B and/or SMAD4 and ATM mutations were most likely PDC. Our results support the previous molecular findings in CCA and PDC."
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • FGFR2 (Fibroblast growth factor receptor 2) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • ATM (ATM serine/threonine kinase) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • BAP1 (BRCA1 Associated Protein 1) • SMAD4 (SMAD family member 4) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • BICC1 (BicC Family RNA Binding Protein 1) • SORBS1 (Sorbin And SH3 Domain Containing 1)
    |
    TP53 mutation • KRAS mutation • KRAS G12C • IDH1 mutation • ATM mutation • FGFR2 mutation • FGFR2 fusion • KRAS G12R • FGFR fusion • BAP1 mutation • KRAS G12 • KRAS Q61H • TP53 mutation + KRAS mutation • FGFR2-SORBS1 fusion • BAP1 mutation + FGFR2 fusion
    |
    Archer® FusionPlex® Comprehensive Thyroid & Lung (CTL) Kit